IP Library Granted Patent US 9,925,222
Granted Patent B2
US 9,925,222 · App. 14/729,211 · Granted Mar 27, 2018

Gut barrier dysfunction treatment and prevention

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,925,222
App. No.
14/729,211
Granted
Mar 27, 2018
Kind
B2
Abstract

Methods are disclosed for treating and preventing gut barrier dysfunction or an illness associated with gut barrier dysfunction in a subject comprising administering to the subject bacterium that produce an indole or an indole metabolite and for identifying compounds and bacteria for use in treatment and prevention of gut barrier dysfunction or an illness associated with gut barrier dysfunction.

Claims (8)

1. A method of treating or preventing gut barrier dysfunction, an illness associated with gut barrier dysfunction, toxic or inflammatory injury to intestines, or leaky intestinal syndrome in a subject comprising administering to the subject a therapeutic effective amount of a bacterium, wherein the bacterium is Clostridium sporogenes comprising a tryptophanase operon, wherein in the presence of tryptophan, the tryptophanase operon is induced and the bacterium produces indole-3-propionic acid or indoleacetic acid from tryptophan,

wherein pregnane X receptor (PXR) is activated in gut apical enterocvtes, thereby decreasing intestinal permeability and inflammation.

2. The method of claim 1 , wherein the bacterium is administered orally to the subject.

3. The method of claim 1 , wherein the subject has irritable bowel syndrome, inflammatory bowel disease, intestinal allergic syndrome or celiac sprue.

4. The method of claim 1 , wherein the bacterium colonizes the gut of the subject.

5. The method of claim 1 , wherein the subject is a human.

6. The method of claim 1 , wherein indole-3-propionic acid or indoleacetic produced by the bacterium induces target genes of PXR in intestinal mucosa in the subject, wherein the target genes are selected from the group consisting of Multi-drug resistant gene (Mdr1), Cytochrome P450, family 3, subfamily a, polypeptide 11 (Cyp3a11) and Uridine diphosphate glucuronosyltransferase family 1 member a1 (Ugt1a1).

7. The method of claim 1 , wherein indole-3-propionic acid or indoleacetic produced by the bacterium reduces a mucosal myeloperoxidase enzyme activity in the subject.

Assignments (5)
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →
CONFIRMATORY LICENSE Recorded May 8, 2018
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046101/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2016
From: MANI, SRIDHAR; MUKHERJEE, SUBHAJIT
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 039620/0007 →
CHANGE OF NAME Recorded Oct 20, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036900/0216 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036877/0885 →